CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview.Bone Marrow Transplant.(2020).
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European.Am J Hematol.(2020).
Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma.Blood Adv4, 1242-1249.(2020).
Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.Bone Marrow Transplant.(2020).
Genotypic and phenotypic characteristics of acute promyelocytic leukemia translocation variants.Hematol Oncol Stem Cell Ther.(2020).
Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party.Biol Blood Marrow Transplant.(2020).
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.Lancet Haematol7, e157-e167.(2020).
Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission.Bone Marrow Transplant.(2020).
Allogeneic stem cell transplantation in therapy-related myelodysplasia after autologous transplantation for lymphoma: a retrospective study of the SFGM-TC.Biol Blood Marrow Transplant.(2019).
Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.Bone Marrow Transplant.(2019).
Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT.Biol Blood Marrow Transplant.(2019).
Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age.Cancer.(2019).
Impact of Cyclosporine-A Concentration on Acute Graft-versus-Host Disease Incidence after Haploidentical Hematopoietic Cell Transplantation.Eur J Haematol.(2019).
Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia.Cancer.(2019).
Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation.Br J Haematol.(2019).
Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.Br J Haematol.(2019).
OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT.Biol Blood Marrow Transplant.(2019).
Risk Factors for Development of and Progression of Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome.Biol Blood Marrow Transplant.(2019).
Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial.Blood.(2019).
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.Br J Haematol.(2019).
Allogeneic Stem Cell Transplantation following Relapse post Autologous Stem Cell Transplantation in adult patients with Acute Myeloid Leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.Am J Hematol.(2018).
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.Cancer.(2018).